| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Dendreon Downgraded, Sort Of.....
Posted on 11/02/2007 11:40:46 | Link | Post Comment
by Jon C. Ogg
24/7 Wall St.
Dendreon (DNDN-NASDAQ) is trading down more than 4% at $21.25 in early trading after JMP Securities downgraded the shares. DNDN closed down 6% at $22.15 yesterday . The “official” rating was cut from a STRONG BUY to that of an Outperform. The reason for the “official” is because of the oddity that while they gave it a downgrade, JMP Securities actually lifted its price target to $24.00 per share from $20.00. The firm believes there is still upside to the stock, but feels valuations are nearing the near-term peak.
We’ll have to see how this one goes as we get closer to that MAY 15 PDUFA at FDA. This one is getting all the buzz in chat rooms today, which can’t be a shock considering how many traders are chatting about this one with volume off the charts.
The stock closed at %22.15 yesterday, and the May $22.50 Calls (May 18 expiration) closed at $5.60 yesterday. This one is still a battleground stock, which is needless to say.
Source: 247WallSt.com
RELATED READING:
- Jim Cramer on Dendreon
- Right on, Dendreon!
- Will Dendreon's Cancer Vaccine Win Final FDA Approval?
__________________________
24/7 Wall St.
Dendreon (DNDN-NASDAQ) is trading down more than 4% at $21.25 in early trading after JMP Securities downgraded the shares. DNDN closed down 6% at $22.15 yesterday . The “official” rating was cut from a STRONG BUY to that of an Outperform. The reason for the “official” is because of the oddity that while they gave it a downgrade, JMP Securities actually lifted its price target to $24.00 per share from $20.00. The firm believes there is still upside to the stock, but feels valuations are nearing the near-term peak.
We’ll have to see how this one goes as we get closer to that MAY 15 PDUFA at FDA. This one is getting all the buzz in chat rooms today, which can’t be a shock considering how many traders are chatting about this one with volume off the charts.
The stock closed at %22.15 yesterday, and the May $22.50 Calls (May 18 expiration) closed at $5.60 yesterday. This one is still a battleground stock, which is needless to say.
Source: 247WallSt.com
RELATED READING:
- Jim Cramer on Dendreon
- Right on, Dendreon!
- Will Dendreon's Cancer Vaccine Win Final FDA Approval?
__________________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
Examples
Morpheus Trading - Thu Jul 17, 2008 01:15AM
NOTE: Please click on the charts below to enlarge them if th [read more]
NOTE: Please click on the charts below to enlarge them if th [read more]
Morpheus Trading - Tue Jul 15, 2008 08:25AM
NOTE: Please click on the charts below to enlarge them [read more]
NOTE: Please click on the charts below to enlarge them [read more]
Morpheus Trading - Mon Jul 14, 2008 02:18AM
NOTE: Please click on the charts below to enlarge them if [read more]
NOTE: Please click on the charts below to enlarge them if [read more]
<< My Home | TheMoneyBlogs Home